Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth
about
ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner.Specific in vivo knockdown of protein function by intrabodiesIdentification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells.Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy.ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependencyHER2/neu antisense targeting of human breast carcinoma.Testing for HER2 in Breast Cancer: A Continuing Evolution.In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins.Targeting the function of the HER2 oncogene in human cancer therapeutics.Novel pharmacological approaches in the treatment of breast cancer.Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis.Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems.A monoclonal antibody to the human c-erbB3 protein stimulates the anchorage-independent growth of breast cancer cell lines.Outgrowth of BT-474 human breast cancer cells in immune-deficient mice: a new in vivo model for hormone-dependent breast cancerTargeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies.Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen.Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells.Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin.c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates.Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 statusThe role of Herceptin in early breast cancerLabeling and Biological Evaluation of (99m)Tc-HYNIC-Trastuzumab as a Potential Radiopharmaceutical for In Vivo Evaluation of HER2 Expression in Breast Cancer.Cancer vaccines inducing antibody production: more pros than cons.In vivo and in vitro activity of an immunoglobulin Fc fragment (Fcab) with engineered Her-2/neu binding sites.In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells.Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition.Increasing of HER2 membranar density in human glioblastoma U251MG cell line established in a new nude mice model.Recombinant humanised anti-HER2/neu antibody (Herceptin) induces cellular death of glioblastomasThe growth and metastasis of human, HER-2/neu-overexpressing tumor cell lines in male SCID mice.Inhibition of signaling from Type 1 receptor tyrosine kinases via intracellular expression of single-chain antibodies.Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells.Growth inhibition by dominant-negative mutations of the neu-encoded oncoprotein.Treatment of large solid tumors in mice with daunomycin-loaded sterically stabilized liposomes.Human tumor growth suppression by apoptosis induced with anti-ErbB-2 chimeric monoclonal antibody.Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma.Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition.Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8⁺ T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice.The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial.
P2860
Q24522643-02BAA88A-8014-4119-BD5E-5453605B24DFQ26801077-E34DD58C-EAB5-4173-B3AD-FD5818AC8FD3Q33205615-61383A11-EEFA-4203-91D8-C950E29DDEA3Q33364005-0FA795AA-0358-466A-8F14-2C1A00496366Q33837881-12D10D08-947A-4F4A-BF29-DB60191BC3AFQ33963261-74B838CE-7382-4239-9A20-AB5491F99534Q34130563-7E18D8F2-C772-465F-835B-1AD84065D64EQ34424285-64A55B90-DE96-4EB4-86F0-480B79AB4AADQ34519479-3731BE27-AA1B-42F0-9B15-1975CBF1ADC8Q34546374-6C4528E7-A271-44C2-8CB8-ECEEC2056C26Q34766486-B65BA033-83E5-4025-A4EF-6CEAF3FBBD12Q35143980-8C2B17E1-F2E6-4C69-949A-33263E3A6FD3Q35230265-F420700A-805F-4E25-8A62-E7950B95AA94Q35949785-02584781-B42E-46B9-A017-7044BE431136Q36079584-8B63EBEC-FFFF-4A60-B68D-D85239808D05Q36081930-B30555E5-CEA8-4530-95D7-CBAA0BB03A27Q36141279-7A755EDA-275C-44B6-8283-7149AF72ED2EQ36167792-7ADE0123-E54A-4E5C-B906-3BE996A45980Q36609570-088FFC08-3094-4D20-A3E3-7B450FB36C38Q36610604-7A5695DD-F087-45D7-923C-E340C569DFBCQ36617940-4F84858A-C7F1-4865-8CBB-30CC232056BCQ36623220-1988DE20-6DFA-45B1-9749-34BF8F1F2076Q36657407-CD8541A9-0A69-44A2-8515-ABF2AB5A3580Q37100372-32BC16B4-9DF4-4C56-9DD8-DEF500D8D0FFQ37932519-6BD38168-EBF1-4B32-B4EA-B355E7F94AADQ38997358-DF336508-9C62-4D01-824A-618AD794CC72Q39042958-A5C61746-4BB5-4758-83D1-4539C25D06C1Q39845394-5F8E0426-7B74-45B8-A53E-85CD0217385CQ40366512-8F6FF9E2-FB7B-4DF9-B2A9-872E899CEEF7Q40522463-5CBCDB63-2F2C-4FD4-BF74-C417A051C408Q40857892-C72DBF41-C69D-4EAB-9345-2BFD8F6B0066Q41125972-5C712DEF-AB55-4742-91F7-2EC233F932A0Q41913443-525741D0-97FA-4611-81D3-89A8567DDA83Q42804900-B77C0BA8-ADF0-4F6B-805B-CB75A3109F94Q42833566-986CD6EB-20D2-4952-8CF0-9FE6BF6984ADQ47759025-C31C8964-1597-432B-B869-48680FAA63A7Q48135134-B767D6F7-F1B8-4BCB-88AD-553CE9D06B05Q49567029-A9D7A99B-84DB-44EC-9803-6F0DF9462BC3Q53248364-B760A459-ECE5-495B-87F5-3B7F8DCA69D1Q53890793-C36A3AC2-A710-442D-B359-99EB0087BC9B
P2860
Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth
@ast
Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth
@en
type
label
Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth
@ast
Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth
@en
prefLabel
Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth
@ast
Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth
@en
P2093
P2860
P356
P1476
Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1993.494
P407
P577
1993-12-01T00:00:00Z